Tuberculosis in patientes treated with tumor necrosis factoralpha antagonists living in an endemic area. Is the risk worthwhile?
Tumor necrosis factor alpha antagonists (TNFA) are biological agents to treat chronicinflammatory and autoimmune diseases. However, their use is associated with an increasedrate of tuberculosis, endemic mycoses, and intracellular bacterial infections. Since tuberculosisis moderately to highly endemi...
Uloženo v:
| Vydáno v: | Biomédica |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Instituto Nacional de Salud
2007
|
| Témata: | |
| On-line přístup: | https://www.redalyc.org/articulo.oa?id=84327203 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|